WO2015076346A1 - Procédé pour produire un dérivé optiquement actif de 2,6-diméthyltyrosine - Google Patents

Procédé pour produire un dérivé optiquement actif de 2,6-diméthyltyrosine Download PDF

Info

Publication number
WO2015076346A1
WO2015076346A1 PCT/JP2014/080811 JP2014080811W WO2015076346A1 WO 2015076346 A1 WO2015076346 A1 WO 2015076346A1 JP 2014080811 W JP2014080811 W JP 2014080811W WO 2015076346 A1 WO2015076346 A1 WO 2015076346A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
dimethyltyrosine
optical purity
derivative
optically active
Prior art date
Application number
PCT/JP2014/080811
Other languages
English (en)
Japanese (ja)
Inventor
西山　章
Original Assignee
株式会社カネカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社カネカ filed Critical 株式会社カネカ
Publication of WO2015076346A1 publication Critical patent/WO2015076346A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a method for producing an optically active 2,6-dimethyltyrosine derivative useful as a pharmaceutical intermediate.
  • (S) -4-acetyl-N-acetyl-2,6-dimethyltyrosine methyl ester is hydrolyzed with an aqueous hydrochloric acid solution and then Boc converted into (S) -N-Boc-2,6-dimethyl.
  • Tyrosine is produced and crystallized from a mixed solvent of ethyl acetate / hexane to obtain 96% ee (S) -N-Boc-2,6-dimethyltyrosine with a yield of 83% (Patent Document 1).
  • an optically active 2,6-dimethyltyrosine derivative having 93% ee is produced by asymmetric hydrogenation, but the optical purity is not improved at all even if crystallization is performed thereafter, and 93% ee.
  • the optically pure object cannot be obtained.
  • the background art 3 has not yet obtained an optically pure optically active 2,6-dimethyltyrosine derivative.
  • a complicated operation of asymmetric hydrolysis using an expensive acylase as in Background Art 2) is further required, and the yield is also reduced. There was a problem.
  • the background technology 1) and the background technology 2) use an ethyl acetate / heptane mixed solvent
  • the background technology 3) uses an ethyl acetate / hexane mixed solvent.
  • the present inventor has found a method for easily producing a high optical purity target by efficiently improving the optical purity of the optically active 2,6-dimethyltyrosine derivative, thereby completing the present invention. It came.
  • R 1 is a hydrogen atom or a protecting group for a phenolic hydroxyl group
  • R 2 is a protecting group for an amino group
  • * represents an asymmetric carbon atom.
  • the optical purity of the compound (1) before the precipitate formation is, for example, 91% ee or less.
  • R 1 is preferably a hydrogen atom or a benzyl group
  • R 2 is preferably a tert-butoxycarbonyl group.
  • An auxiliary solvent may be further mixed with the organic solvent.
  • the organic solvent is preferably at least one of isopropyl acetate, methyl tert-butyl ether, tetrahydrofuran, ethanol, isopropanol, acetone, methyl isobutyl ketone, or acetonitrile, and the auxiliary solvent is preferably hexane or heptane.
  • the compound (1) is, for example, the following formula (2); (Wherein R 3 represents a hydrogen atom or a protecting group for a phenolic hydroxyl group; X represents a chlorine atom, a bromine atom or an iodine atom) and the following formula (3); Wherein R 4 represents a hydrogen atom or an aryl group having 6 to 12 carbon atoms which may have a substituent, and R 5 represents an aryl group having 6 to 12 carbon atoms which may have a substituent.
  • R 6 represents an alkyl group having 1 to 12 carbon atoms.
  • a glycine Schiff base represented by the following formula (4) By reacting a glycine Schiff base represented by the following formula (4) with a base in the presence of an optically active phase transfer catalyst: (Wherein R 3 , R 4 , R 5 , R 6 , * are the same as above), and can be produced by further hydrolyzing and then protecting the amino group. It is.
  • R 3 is preferably an ethoxycarbonyl group or a benzyl group
  • R 4 is preferably a hydrogen atom or a phenyl group
  • R 5 is preferably a phenyl group
  • R 6 is preferably an ethyl group or a tert-butyl group
  • the absolute configuration is S is preferred.
  • Examples of the base include potassium hydroxide
  • examples of the optically active phase transfer catalyst include (11bR)-( ⁇ )-4,4-dibutyl-4,5-dihydro-2,6- Bis (3,4,5-trifluorophenyl) -3H-dinaphtho [2,1-c: 1 ′, 2′-e] azepinium bromide, (15bR) -14,14-dibutyl-5,6 7,8,14,15-Hexahydro-1,12-bis (3,4,5-trifluorophenyl) -13H- [1,6] benzodioxetino [9.8,7-def] [2] Benzazepinium bromide or N- (2-chlorobenzyl) cinconidinium bromide can be used.
  • an optically active 2,6-dimethyltyrosine derivative having a high optical purity required for a pharmaceutical intermediate can be easily and efficiently produced.
  • optically active 2,6-dimethyltyrosine derivative has the following formula (1):
  • R 1 represents a hydrogen atom or a protecting group for a phenol hydroxyl group.
  • the protecting group for the phenolic hydroxyl group include ether-type protecting groups such as aliphatic hydrocarbon groups (such as methyl, allyl and tert-butyl groups) and aralkyl groups (such as benzyl and p-nitrobenzyl groups); acyl Ester-type protecting groups such as groups (acetyl group, pivaloyl group, benzoyl group, trifluoroacetyl group, etc.); alkoxycarbonyl groups (methoxycarbonyl group, ethoxycarbonyl group, isopropoxycarbonyl group, tert-butoxycarbonyl group, etc.), allyl Carbonate-type protecting groups such as oxycarbonyl group and benzyloxycarbonyl group; silyl groups such as trimethylsilyl group, triethylsilyl group, tert-butyldi
  • R 2 represents an amino-protecting group.
  • Carbamate-type protecting groups such as alkoxycarbonyl groups (methoxycarbonyl group, ethoxycarbonyl group, isopropoxycarbonyl group, tert-butoxycarbonyl group), allyloxycarbonyl group, benzyloxycarbonyl group, fluoren-9-ylmethoxycarbonyl group, etc.
  • Acyl-type protecting groups such as formyl group, acetyl group, trifluoroacetyl group, pivaloyl group, benzoyl group and p-nitrobenzoyl group; sulfonyl-type protecting groups such as mesyl group, p-toluenesulfonyl group and p-nitrobenzenesulfonyl group And more preferably a tert-butoxycarbonyl group or a benzyloxycarbonyl group, and particularly preferably a tert-butoxycarbonyl group.
  • * In the formula (1) represents an asymmetric carbon atom.
  • the optically active 2,6-dimethyltyrosine derivative preferably has S in absolute configuration.
  • the optical purity of the 2,6-dimethyltyrosine derivative that can be used in the present invention is preferably 30% ee or more, more preferably 50% ee or more, and particularly preferably 70% ee or more.
  • a 2,6-dimethyltyrosine derivative having a high optical purity that is acceptable as a pharmaceutical intermediate can be produced from such an optically pure starting material by the production method of the present invention.
  • the production method of the 2,6-dimethyltyrosine derivative is not particularly limited.
  • the asymmetric hydrogenation method described in Non-Patent Document 1 or Patent Document 1 (see the following formula (A)) Is mentioned.
  • Tetrahedron Asymmetry 2000, 11, 2917-2925.
  • An optically active 2,6-dimethyltyrosine derivative may be produced using a chiral synthon as described in (see formula (B) below).
  • an arylmethyl halide compound and a glycine Schiff base are reacted in the presence of a base and an optically active phase transfer catalyst, then the reaction product is hydrolyzed, and the amino group is protected. Yes (see formula (C) below).
  • the arylmethyl halide compound has the following formula (2):
  • R 3 represents a hydrogen atom or a protecting group for a phenol hydroxyl group.
  • protecting groups for phenolic hydroxyl groups include ether type protecting groups such as aliphatic hydrocarbon groups (such as methyl, allyl and tert-butyl groups) and aralkyl groups (such as benzyl and p-nitrobenzyl groups); acyl groups ( Ester-type protecting groups such as acetyl group, pivaloyl group, benzoyl group, trifluoroacetyl group, etc .; alkoxycarbonyl groups (methoxycarbonyl group, ethoxycarbonyl group, isopropoxycarbonyl group, tert-butoxycarbonyl group, etc.), allyloxycarbonyl Carbonate-type protecting groups such as benzyloxycarbonyl group; silyl groups such as trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl
  • X represents a chlorine atom, a bromine atom, or an iodine atom.
  • a bromine atom or an iodine atom is preferable.
  • the synthesis method of 4-benzyloxy-2,6-dimethylbenzyl bromide is Tetrahedron Asymmetry, 2000, 11, 2917-2925.
  • the method for synthesizing 4-iodomethyl-3,5-dimethylphenyl ethyl carbonate is described in Tetrahedron Asymmetry, 2009, 20, 1398-1401. It can be used as a reference.
  • the glycine Schiff base has the following formula (3):
  • R 4 represents a hydrogen atom or an aryl group having 6 to 12 carbon atoms which may have a substituent.
  • a hydrogen atom, a phenyl group, and a p-chlorophenyl group are preferable, and a hydrogen atom or a phenyl group is more preferable.
  • R 5 represents an aryl group having 6 to 12 carbon atoms which may have a substituent.
  • a phenyl group, a p-methylphenyl group, a p-chlorophenyl group, a p-nitrophenyl group, and a p-methoxyphenyl group are preferable, and a phenyl group is more preferable.
  • R 4 and R 5 are aryl groups
  • R 4 and R 5 may be the same as or different from each other.
  • R 6 represents an alkyl group having 1 to 12 carbon atoms. A methyl group, an ethyl group, an isopropyl group, a tert-butyl group, or a benzyl group is preferable, and an ethyl group or a tert-butyl group is more preferable.
  • the amount of the glycine Schiff base (3) to be used is preferably 1 to 10 equivalents (fold molar amount), more preferably 1 to 3 equivalents, and particularly preferably the arylmethyl halide (2). 1.1 to 1.5 equivalents.
  • reaction product (hereinafter sometimes referred to as tyrosine Schiff base) is represented by the following formula (4);
  • R 3 , R 4 , R 5 and R 6 are the same as described above. * Represents an asymmetric carbon atom, and S is preferably the absolute configuration.
  • Examples of the base include metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide; carbonates such as sodium carbonate, potassium carbonate, and cesium carbonate.
  • Sodium hydroxide or potassium hydroxide is preferable, and potassium hydroxide is more preferable.
  • the amount of the base used is preferably 0.5 to 50 equivalents (double molar amount), more preferably 1 to 10 equivalents, relative to the aryl methyl halide (2).
  • optically active phase transfer catalyst examples include an optically active quaternary ammonium salt phase transfer catalyst and an optically active phase transfer catalyst complexed with metal atoms.
  • an optically active quaternary ammonium salt having a biphenyl skeleton and / or a binaphthyl skeleton, an optically active tartaric acid type quaternary ammonium salt, an optically active benzazepine type quaternary ammonium salt, or an optically active cinchona alkaloid type quaternary ammonium
  • examples thereof include a salt, or a nickel or copper catalyst complexed with an N, N′-bis (salicylidene) -1,2-cyclohexanediamine derivative (Jacobsen ligand).
  • a particularly preferred catalyst is an optically active quaternary ammonium salt having a biphenyl skeleton and / or a binaphthyl skeleton, an optically active benzazepine-type quaternary ammonium salt, or an optically active cinchona alkaloid-type quaternary ammonium salt.
  • the upper limit is preferably 1 equivalent (times mol) to the arylmethyl halide (2), and more preferably. Is 0.5 equivalent, particularly preferably 0.1 equivalent.
  • the lower limit is preferably 0.0001 equivalent, more preferably 0.001 equivalent, and particularly preferably 0.01 equivalent with respect to the arylmethyl halide (2).
  • the solvent for this reaction is not particularly limited as long as it does not affect the reaction.
  • alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol, and ethylene glycol are used.
  • Solvents; ether solvents such as tetrahydrofuran, diethyl ether, 1,4-dioxane, methyl tert-butyl ether, ethylene glycol dimethyl ether; nitrile solvents such as acetonitrile and propionitrile; ethyl acetate, n-propyl acetate, isopropyl acetate, etc.
  • Ester solvents aliphatic hydrocarbon solvents such as pentane, hexane, heptane and methylcyclohexane; aromatic hydrocarbon solvents such as benzene, toluene, xylene, ethylbenzene and mesitylene; acetone and methyl Ketone solvents such as tilketone; halogen solvents such as methylene chloride and 1,2-dichloroethane; sulfoxide solvents such as dimethyl sulfoxide; N, N-dimethylformamide, N, N-dimethylacetamide, N, N-diethylacetamide, Amide solvents such as N-methyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, N-methyl- ⁇ -caprolactam, hexamethylphosphoramide; urea solvents such as dimethylpropylene urea; hexamethylphosphonic acid triamide, etc.
  • aromatic hydrocarbon solvents
  • a phosphonic acid triamide solvent or the like can be used. These may be used alone or in combination of two or more. When using 2 or more types together, the mixing ratio is not particularly limited.
  • ether solvents such as tetrahydrofuran, diethyl ether, 1,4-dioxane, methyl tert-butyl ether, ethylene glycol dimethyl ether; hydrocarbon solvents such as pentane, hexane, heptane; benzene, toluene, xylene, ethylbenzene, mesitylene, etc.
  • Aromatic hydrocarbon solvents such as methylene chloride and 1,2-dichloroethane, more preferably tetrahydrofuran, methyl tert-butyl ether, hexane, heptane, toluene, xylene, ethylbenzene, mesitylene, methylene chloride, or 1 2-dichloroethane, particularly preferably toluene, xylene, ethylbenzene, or mesitylene.
  • halogen solvents such as methylene chloride and 1,2-dichloroethane, more preferably tetrahydrofuran, methyl tert-butyl ether, hexane, heptane, toluene, xylene, ethylbenzene, mesitylene, methylene chloride, or 1 2-dichloroethane, particularly preferably toluene, xylene, ethylbenz
  • the upper limit is preferably 100 times weight, more preferably 50 times weight with respect to the arylmethyl halide (2). Yes, particularly preferably 20 times the weight.
  • the lower limit is preferably 0.1 times the weight, more preferably 0.5 times the weight, and particularly preferably 1 times the weight with respect to the arylmethyl halide (2).
  • the amount of water used is preferably 1 to 100 equivalents (fold moles), more preferably 3 to 30 equivalents, relative to the aryl methyl halide (2).
  • the reaction temperature in this reaction is not particularly limited and may be set as appropriate.
  • the upper limit is preferably 120 ° C., more preferably 50 ° C., and particularly preferably 30 ° C.
  • the lower limit is preferably ⁇ 80 ° C., more preferably ⁇ 50 ° C., and particularly preferably ⁇ 20 ° C.
  • the reaction time in this reaction is not particularly limited and may be appropriately set.
  • the upper limit is preferably 120 hours, more preferably 100 hours, and particularly preferably 80 hours.
  • the lower limit is preferably 0.1 hour, more preferably 1 hour, and particularly preferably 3 hours.
  • a general process for obtaining a product from the reaction solution may be performed.
  • the reaction solution after completion of the reaction is subjected to an extraction operation using water, a general extraction solvent such as ethyl acetate, diethyl ether, methylene chloride, toluene, hexane and the like.
  • a general extraction solvent such as ethyl acetate, diethyl ether, methylene chloride, toluene, hexane and the like.
  • the target product thus obtained has a sufficient purity that can be used in the subsequent steps.
  • crystallization, fractional distillation, solution washing, column chromatography, etc. are generally used.
  • the purity may be further increased by a simple purification method.
  • an optically active 2,6-dimethyltyrosine is produced by hydrolyzing the protecting group of the tyrosine Schiff base (4), an ester, and optionally a phenol hydroxyl protecting group, and further protecting the amino group.
  • An optically active 2,6-dimethyltyrosine derivative represented by the formula (1) can be produced.
  • the hydrolysis is preferably acid hydrolysis, and the acid is preferably hydrochloric acid, hydrobromic acid, sulfuric acid or the like.
  • the amount of the acid used is preferably 1 to 100 equivalents, more preferably 3 to 30 equivalents, relative to the tyrosine Schiff base (4).
  • the amount of water used is preferably 1 to 100 times the weight, more preferably 3 to 30 times the weight of the tyrosine Schiff base (4).
  • the reaction temperature in this hydrolysis is not particularly limited and may be appropriately set.
  • the upper limit is preferably 120 ° C., and more preferably 100 ° C.
  • it is 0 degreeC as a minimum, More preferably, it is 20 degreeC.
  • Protecting conditions for amino groups may be appropriately set according to the type of protecting group. Specifically, for example, when tert-butoxycarbonyl protection or benzyloxycarbonyl protection is performed, an aqueous solution of optically active 2,6-dimethyltyrosine obtained by the hydrolysis is added with sodium hydroxide, potassium hydroxide, sodium carbonate, After neutralization by adding a base such as potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, dibock (ie di-tert-butyl dicarbonate) or benzyloxycarbonyl chloride may be added. For the purpose of accelerating the reaction, the base may be further added to control the pH during the reaction to 7 or more.
  • a base such as potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, dibock (ie di-tert-butyl dicarbonate) or benzyloxycarbonyl chloride may be added.
  • the base may be further added to control the pH during the reaction to 7 or more.
  • the optically active 2,6-dimethyltyrosine derivative (1) thus obtained has a sufficient purity that can be used in the subsequent steps.
  • a general method such as column chromatography is used.
  • the purity may be further increased by a purification method.
  • any of the optically active 2,6-dimethyltyrosine derivatives (1) produced by the method described above preferably has an optical purity acceptable as a pharmaceutical intermediate such as 98% ee or more, more preferably 99% ee or more.
  • an optical purity acceptable as a pharmaceutical intermediate such as 98% ee or more, more preferably 99% ee or more.
  • the present inventor preferentially precipitated the 2,6-dimethyltyrosine derivative (1) having a low optical purity as a solid from an organic solvent, whereby the 2,6-dimethyltyrosine derivative ( 1)
  • the optical purity of the optically active 2,6-dimethyltyrosine derivative (1) having high optical purity was successfully developed by improving the optical purity.
  • the 2,6-dimethyltyrosine derivative is considered to cause preferential crystallization in which the crystallized product has higher optical purity than the mother liquor (or at least the optical purity of the crystallized product does not decrease)
  • Non-patent Document 1 and Patent Document 1 described above 2,6-dimethyltyrosine derivatives were crystallized based on this idea. Contrary to these conventional ideas, specific 2,6-dimethyltyrosine derivatives (1) The present inventors have found that the optical purity of the crystallized product is poor and the optical purity of the mother liquor is increased.
  • organic solvent examples include ester solvents such as ethyl acetate, isopropyl acetate, and methyl propionate; ether solvents such as tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, and tert-butyl methyl ether; methanol, ethanol, isopropanol Alcohol solvents such as N-butanol and ethylene glycol; ketone solvents such as acetone, methyl ethyl ketone, acetophenone and methyl isobutyl ketone; nitrile solvents such as acetonitrile, propionitrile and benzonitrile; N, N-dimethylformamide, N , N-dimethylacetamide, N, N-diethylformamide, N, N-dipropylformamide, N, N-dibutylformamide, dimethyl sulfoxide, N-methylpyrrolidone, 1,
  • the said organic solvent may be used independently and may be used in mixture of 2 or more types.
  • the mixing ratio is not particularly limited. If the amount of the solvent used is too large, it is not preferable in terms of cost and post-treatment, and therefore the upper limit is preferably 100 times or less, more preferably 50 times the weight of the 2,6-dimethyltyrosine derivative (1). Less than weight.
  • the lower limit is preferably 1-fold weight or more, more preferably 3-fold weight or more with respect to the 2,6-dimethyltyrosine derivative (1).
  • an auxiliary solvent may be added from the viewpoint of improving the recovery rate, improving the purity, and ensuring fluidity.
  • the auxiliary solvent include water; aliphatic hydrocarbon solvents such as hexane and heptane; halogen solvents such as dichloromethane, 1,2-dichloroethane, chloroform and chlorobenzene; aromatic hydrocarbons such as toluene, xylene and mesitylene. And system solvents. Preferred are water, hexane, heptane, methylene chloride and toluene, and more preferred is hexane or heptane.
  • the auxiliary solvent may be used alone or in combination of two or more. When mixing, the mixing ratio is not particularly limited.
  • the upper limit is preferably 100 times or less, more preferably 50 times the weight of the 2,6-dimethyltyrosine derivative (1). Less than weight.
  • the lower limit is preferably 1 or more times the weight, more preferably 3 or more times the weight of the compound (1).
  • the ratio thereof can be appropriately set according to the type of the solvent.
  • the amount of the organic solvent is, for example, 10 with respect to the total of the organic solvent and the auxiliary solvent. About 90% by weight, preferably about 20-80% by weight.
  • the amount of organic solvent is, for example, relative to the sum of the organic solvent and auxiliary solvent, It is about 10 to 80% by weight, preferably about 20 to 60% by weight, and more preferably about 25 to 45% by weight.
  • the method for precipitating the optically active 2,6-dimethyltyrosine derivative of low optical purity as a solid is not particularly limited, and examples thereof include the following methods.
  • A A method in which an optically active 2,6-dimethyltyrosine derivative is dissolved in an organic solvent and then cooled to precipitate a solid.
  • B A method in which an optically active 2,6-dimethyltyrosine derivative is dissolved in an organic solvent and then concentrated to precipitate a solid.
  • C A method of precipitating a solid by dissolving an optically active 2,6-dimethyltyrosine derivative in an organic solvent and further adding an auxiliary solvent.
  • D A method of precipitating a solid by dissolving an optically active 2,6-dimethyltyrosine derivative in an organic solvent and then concentrating and substituting with an auxiliary solvent.
  • solids may be precipitated by appropriately combining the methods (a) to (d). Further, when the solid is precipitated, a seed solid may be added.
  • the solid used as a seed include low optical purity (for example, 50% ee or less, preferably 30% ee or less, more preferably 10% ee or less), particularly racemic 2, which is an equivalent mixture of S and R isomers. 6-dimethyltyrosine derivatives are preferred.
  • the implementation temperature in the method for depositing solids (a) to (d) is not particularly limited. Preferably, the temperature may be set below the temperature at which the optically active 2,6-dimethyltyrosine derivative is dissolved in the solvent species or mixed solvent species to be used, depending on the target precipitation amount and solid quality.
  • optically active 2,6-dimethyltyrosine derivative of low optical purity deposited by the method of depositing the solids (a) to (d) is removed or separated by a method such as vacuum filtration, pressure filtration, or centrifugation. Can do. If the optical purity of the optically active 2,6-dimethyltyrosine derivative in the mother liquor is not sufficiently improved, the method of precipitating any of the solids (a) to (d) may be repeated again.
  • the optical purity of the 2,6-dimethyltyrosine derivative (1) before precipitation is, for example, It may be 91% ee or less, 90% ee or less, 85% ee or less, or 80% ee or less. Even from such low optical purity, the 2,6-dimethyltyrosine derivative (1) having high photochemical purity can be left in the mother liquor.
  • the optical purity of the 2,6-dimethyltyrosine derivative (1) before precipitation is, for example, 30% ee or more, preferably 50% ee or more, and more preferably 70% ee or more.
  • the optical purity (E 2 ) of the 2,6-dimethyltyrosine derivative (1) that precipitates may be lower than the optical purity (E 1 ) before the precipitation.
  • the optical purity (E 3 ) of the 2,6-dimethyltyrosine derivative (1) in the mother liquor can be increased by making the optical purity (E 2 ) of the precipitate lower than the optical purity before precipitation (E 1 ).
  • the difference (E 1 -E 2 ) between the optical purity (E 1 ) before precipitation and the optical purity (E 2 ) of the precipitate is, for example, 5% ee or more, preferably 20% ee or more, more preferably 40% ee. That's it.
  • the upper limit of the difference (E 1 ⁇ E 2 ) is not particularly limited. For example, it is 95% ee or less, preferably 80% ee or less, and may be 60% ee or less.
  • the amount of precipitated 2,6-dimethyltyrosine derivative (1) (A 2 ) is, for example, 1% by weight relative to the amount of 2,6-dimethyltyrosine derivative (1) before precipitation (A 1 ). Above, preferably 5% by weight or more, more preferably 10% by weight or more. The greater the amount (A 2 ) of the precipitate having low optical purity, the higher the optical purity of the mother liquor.
  • the upper limit of the amount of precipitate (A 2 ) is, for example, 60% by weight or less, preferably 40% by weight or less, relative to the amount (A 1 ) of the 2,6-dimethyltyrosine derivative (1) before precipitation. More preferably, it is 20% by weight or less, particularly 15% by weight or less.
  • the optical purity (E 3 ) of the 2,6-dimethyltyrosine derivative (1) in the mother liquor is, for example, 85% ee or more, preferably 90% ee or more, more preferably 95% ee or more, particularly preferably 98% ee. That's it.
  • the amount (A 3 ) of the 2,6-dimethyltyrosine derivative (1) in the mother liquor is, for example, 40% by weight or more with respect to the amount (A 1 ) of the 2,6-dimethyltyrosine derivative (1) before precipitation.
  • the amount is preferably 60% by weight or more, more preferably 80% by weight or more, and particularly preferably 8% by weight or more, for example, 99% by weight or less, 95% by weight or less, or 90% by weight or less.
  • the organic solvent and auxiliary solvent are distilled off by an operation such as heating under reduced pressure to thereby improve optical purity of optically active 2,6-dimethyl.
  • a tyrosine derivative can be obtained.
  • a target product having a high optical purity of 99% ee or more can be obtained as a solid.
  • the first solid precipitation / solid-liquid separation treatment (recrystallization) is performed in the next solid precipitation / solid-liquid separation treatment (recrystallization).
  • the precipitated solid tends to have higher optical purity than the mother liquor.
  • the extent to which the optical purity on the mother liquor side can be increased by solid precipitation / solid-liquid separation treatment will increase the optical purity of the precipitated solid by the next solid precipitation / solid-liquid separation treatment. Can be easily set experimentally.
  • the optical purity of the 2,6-dimethyltyrosine derivative on the mother liquor side is increased in the first solid precipitation / solid-liquid separation treatment, and the optical purity on the precipitate side in the next solid precipitation / solid-liquid separation treatment. It is possible to make the equipment common or shared in the first and subsequent solid precipitation / solid-liquid separation processes. Therefore, the equipment burden can be reduced. In addition, the target having high optical purity can be finally recovered as a solid separated from the liquid (mother liquid), and impurities other than the optical isomer can be easily removed.
  • Example 2 Synthesis of (S) -N-Boc-2,6-dimethyltyrosine N- (diphenylmethylene) glycine tert-butyl ester (384 mg, 1.3 mmol), N- (2-chlorobenzyl) cinchodi To a solution of nitrobromide (46 mg, 10 mol%), 85 wt% potassium hydroxide (330 mg, 5 mmol), water (234 mg), toluene (10 mL), 4-iodomethyl-3,5-dimethylphenyl ethyl carbonate (73.
  • a toluene solution (1.5 mL) of 4 wt%, 455 mg, 1 mmol) was added at 5 ° C. and stirred for 20 hours.
  • Water (10 mL) was added for washing, and water (10 mL) and concentrated hydrochloric acid (1 mL) were added to the organic layer, followed by stirring at 90 ° C. for 5 hours.
  • the organic layer was separated and the aqueous layer was washed with toluene (3 mL).
  • Tetrahydrofuran (5 mL), potassium carbonate (1105 mg, 8 mmol), and ditert-butyl dicarbonate (327 mg, 1.5 mmol) were sequentially added, and the mixture was stirred at 25 ° C. for 16 hours.
  • a toluene solution (10 mL) of (73.0 wt%, 915 mg, 2 mmol) was added at 5 ° C. and stirred for 3 hours.
  • Water (10 mL) was added for washing, and water (8 mL) and concentrated hydrochloric acid (2083 mg, 20 mmol) were added to the organic layer, followed by stirring at 90 ° C. for 16 hours. After cooling to room temperature, the organic layer was separated and the aqueous layer was washed with toluene (5 mL).
  • Tetrahydrofuran (5 mL), potassium carbonate (2211 mg, 16 mmol) and ditert-butyl dicarbonate (654 mg, 3 mmol) were sequentially added, and the mixture was stirred at 40 ° C. for 3 hours. After cooling to room temperature, the pH was adjusted to 2 with concentrated hydrochloric acid, and the mixture was extracted with ethyl acetate (20 mL). The organic layer was washed twice with water (5 mL) and concentrated under reduced pressure to give the title compound as a brown oil (yield: 88%, optical purity: 82.6% ee).
  • a toluene solution (10 mL) of ⁇ 3,5-dimethylphenyl ethyl carbonate (73.0 wt%, 915 mg, 2 mmol) was added at 20 ° C., and 2 And the mixture was stirred time.
  • Water (10 mL) was added for washing, and water (8 mL) and concentrated hydrochloric acid (2083 mg, 20 mmol) were added to the organic layer, followed by stirring at 90 ° C. for 5 hours. After cooling to room temperature, the organic layer was separated and the aqueous layer was washed with toluene (5 mL).
  • Example 14 Purification of (S) -N-Boc-2,6-dimethyltyrosine Crude (S) -N-Boc-2,6-dimethyltyrosine (55.6 wt%, prepared in Example 1) Acetone (10 mL) and hexane (15 mL) were added to 3.0 g (5.4 mmol) of optical purity: 88.9% ee). When a racemic seed crystal was added thereto, a solid was precipitated. After stirring at 25 ° C. for 1 hour, the solid was filtered under reduced pressure (yield: 7%, solid optical purity: 9.2% ee, mother liquid optical purity: 98.0% ee).
  • Example 15 Purification of (S) -N-Boc-2,6-dimethyltyrosine Crude (S) -N-Boc-2,6-dimethyltyrosine (55.6% by weight, prepared in Example 1) Acetone (10 mL) and hexane (25 mL) were added to 3.0 g (5.4 mmol) of optical purity: 88.9% ee). When a racemic seed crystal was added thereto, a solid was precipitated. After stirring at 25 ° C. for 1 hour, the solid was filtered under reduced pressure (yield: 8%, optical purity of solid: 11.0% ee, optical purity of mother liquor: 99.0% ee).
  • the present invention can be used for the production of an optically active 2,6-dimethyltyrosine derivative useful as a pharmaceutical intermediate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention porte sur un dérivé 2,6-diméthyltyrosine optiquement actif représenté par la formule (1) (dans laquelle R1 représente un atome d'hydrogène ou un groupe protecteur de groupe phénol R2 représente un groupe protecteur de groupe amino; et * représente un atome de carbone asymétrique) et ayant une pureté optique améliorée pouvant être produit par précipitation et élimination d'un matériau solide ayant une faible pureté optique d'une solution comprenant le dérivé 2,6-diméthyltyrosine optiquement actif et un solvant organique pour améliorer la pureté optique du dérivé dans la liqueur mère.
PCT/JP2014/080811 2013-11-21 2014-11-20 Procédé pour produire un dérivé optiquement actif de 2,6-diméthyltyrosine WO2015076346A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-240537 2013-11-21
JP2013240537A JP2017014109A (ja) 2013-11-21 2013-11-21 光学活性２，６−ジメチルチロシン誘導体の製造法

Publications (1)

Publication Number Publication Date
WO2015076346A1 true WO2015076346A1 (fr) 2015-05-28

Family

ID=53179606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/080811 WO2015076346A1 (fr) 2013-11-21 2014-11-20 Procédé pour produire un dérivé optiquement actif de 2,6-diméthyltyrosine

Country Status (2)

Country Link
JP (1) JP2017014109A (fr)
WO (1) WO2015076346A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987302A (zh) * 2015-06-24 2015-10-21 江苏苏利精细化工股份有限公司 N,n-二乙基-甲酸4-卤代甲基-3,5-二甲基-苯酚酯化合物及其制备方法
WO2017043626A1 (fr) * 2015-09-11 2017-03-16 株式会社カネカ Procédé de production d'un dérivé 4-carbamoyl-2,6-diméthylphénylalanine optiquement actif

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
JP2000247945A (ja) * 1999-02-23 2000-09-12 Mitsui Chemicals Inc 光学活性Ｎ−ｔ−ブトキシカルボニルフェニルアラニンエステルの精製法
JP2000264870A (ja) * 1999-03-19 2000-09-26 Mitsui Chemicals Inc 光学活性Ｎ−ｔ−ブトキシカルボニルフェニルアラニンエステルの製造方法
WO2005073196A1 (fr) * 2004-01-30 2005-08-11 Nagase & Co., Ltd. SEL D’AMMONIUM QUATERNAIRE OPTIQUEMENT ACTIF AYANT UNE ASYMETRIE AXIALE ET PROCESSUS DE PRODUCTION D’UN ACIDE α-AMINO ET DE SON DERIVE AVEC CELUI-CI
WO2007013698A1 (fr) * 2005-07-29 2007-02-01 Nagase & Co., Ltd. Procede de fabrication d'un compose alkyle mono-substitue utilisant de l'aldimine ou un derive d'aldimine
JP2010132646A (ja) * 2008-11-07 2010-06-17 Mitsubishi Rayon Co Ltd 光学活性Ｎ−アルコキシカルボニル−ｔｅｒｔ−ロイシンの製造方法
JP2012250943A (ja) * 2011-06-03 2012-12-20 Kaneka Corp 光学活性２，６−ジメチルフェニルアラニン誘導体の製造法
WO2013058241A1 (fr) * 2011-10-18 2013-04-25 株式会社カネカ Procédé de production de (r)-2-amino-éthylhexanol

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
JP2000247945A (ja) * 1999-02-23 2000-09-12 Mitsui Chemicals Inc 光学活性Ｎ−ｔ−ブトキシカルボニルフェニルアラニンエステルの精製法
JP2000264870A (ja) * 1999-03-19 2000-09-26 Mitsui Chemicals Inc 光学活性Ｎ−ｔ−ブトキシカルボニルフェニルアラニンエステルの製造方法
WO2005073196A1 (fr) * 2004-01-30 2005-08-11 Nagase & Co., Ltd. SEL D’AMMONIUM QUATERNAIRE OPTIQUEMENT ACTIF AYANT UNE ASYMETRIE AXIALE ET PROCESSUS DE PRODUCTION D’UN ACIDE α-AMINO ET DE SON DERIVE AVEC CELUI-CI
WO2007013698A1 (fr) * 2005-07-29 2007-02-01 Nagase & Co., Ltd. Procede de fabrication d'un compose alkyle mono-substitue utilisant de l'aldimine ou un derive d'aldimine
JP2010132646A (ja) * 2008-11-07 2010-06-17 Mitsubishi Rayon Co Ltd 光学活性Ｎ−アルコキシカルボニル−ｔｅｒｔ−ロイシンの製造方法
JP2012250943A (ja) * 2011-06-03 2012-12-20 Kaneka Corp 光学活性２，６−ジメチルフェニルアラニン誘導体の製造法
WO2013058241A1 (fr) * 2011-10-18 2013-04-25 株式会社カネカ Procédé de production de (r)-2-amino-éthylhexanol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI,ZHI ET AL., GAODENG XUEXIAO HUAXUE XUEBAO, vol. 31, no. 8, 2010, pages 1564 - 1569 *
NORIAKI HIRAYAMA, YUKI KAGOBUTSU KESSHO SAKUSEI HANDBOOK -GENRI TO KNOW-HOW, 2008, pages 78, 79 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987302A (zh) * 2015-06-24 2015-10-21 江苏苏利精细化工股份有限公司 N,n-二乙基-甲酸4-卤代甲基-3,5-二甲基-苯酚酯化合物及其制备方法
WO2017043626A1 (fr) * 2015-09-11 2017-03-16 株式会社カネカ Procédé de production d'un dérivé 4-carbamoyl-2,6-diméthylphénylalanine optiquement actif
CN108026032A (zh) * 2015-09-11 2018-05-11 株式会社钟化 光学活性4-氨基甲酰基-2,6-二甲基苯基丙氨酸衍生物的制造方法
CN108026032B (zh) * 2015-09-11 2020-09-29 株式会社钟化 光学活性4-氨基甲酰基-2,6-二甲基苯基丙氨酸衍生物的制造方法

Also Published As

Publication number Publication date
JP2017014109A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
CN108718527B (zh) 用于制备化合物的方法
CA2610776C (fr) Procede de fabrication d'un compose alkyle mono-substitue utilisant de l'aldimine ou un derive d'aldimine
CN1986516A (zh) 制备富对映体2－烷氧基－3－苯基丙酸的方法
US9115052B2 (en) Separation of an enantiomer mixture of (R)- and (S)-3-amino-1-butanol
JP2009531313A5 (fr)
WO2003064420A1 (fr) Nouveaux composes optiquement actifs, procede de resolution optique cinetique de derives d'acide carboxylique, et catalyseurs y relatifs
WO2015076346A1 (fr) Procédé pour produire un dérivé optiquement actif de 2,6-diméthyltyrosine
US9828340B2 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
CN112154140B (zh) 化合物及其在合成布瓦西坦(Brivaracetam)原料药中的用途
CN114901644A (zh) 制备右美托咪定的方法
JP4356060B2 (ja) 光学活性１−保護インドリン−２−カルボン酸誘導体の製造方法および光学活性インドリン−２−カルボン酸誘導体の製造方法
CN107814757B (zh) 一种合成多取代吡咯衍生物的方法
CN113121549B (zh) 立体选择性合成手性内酯的方法和手性化合物及其应用
CN112707899B (zh) 一种奎宁醇的制备方法
JP2005501028A (ja) ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離
CN109020788B (zh) 光学纯的1,1’-螺二氢茚-6,6’-二醇衍生物的制备方法
EP2643284B1 (fr) Procédé de synthèse d'un acide 2,2'-dihydroxy-1,1'-binaphtyl-3-carboxylique énantiomériquement pur
WO2013011999A1 (fr) Procédé pour produire un dérivé optiquement actif de 2-méthylproline
JP2014031327A (ja) 光学活性シス−２−アミノ−シクロヘキサンカルボン酸誘導体およびその前駆体の製造法
CN111094260B (zh) 化合物及其在合成布瓦西坦(Brivaracetam)中间体及原料药中的用途
JP2008115178A (ja) ジフェニルアラニン−Ｎｉ（ＩＩ）錯体の製造方法
JP4168416B2 (ja) 光学活性アミノペンタンニトリルの製造方法
JP2008133261A (ja) 不斉銅錯体結晶の製造方法
WO2010071117A1 (fr) Procédé de fabrication de (s)-1-phényl-1,2,3,4-tétrahydroisoquinoléine
JP5981719B2 (ja) 光学活性チアゾリルアラニン誘導体およびその塩の製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14863723

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 14863723

Country of ref document: EP

Kind code of ref document: A1